Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

BACKGROUND: The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public health emergency and the absence of efficacious drugs or vaccines, MERS is one of the WHO priority diseases warranting ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Till, Dahlke, Christine, Fathi, Anahita, Kupke, Alexandra, Krähling, Verena, Okba, Nisreen M A, Halwe, Sandro, Rohde, Cornelius, Eickmann, Markus, Volz, Asisa, Hesterkamp, Thomas, Jambrecina, Alen, Borregaard, Saskia, Ly, My L, Zinser, Madeleine E, Bartels, Etienne, Poetsch, Joseph S H, Neumann, Reza, Fux, Robert, Schmiedel, Stefan, Lohse, Ansgar W, Haagmans, Bart L, Sutter, Gerd, Becker, Stephan, Addo, Marylyn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172913/
https://www.ncbi.nlm.nih.gov/pubmed/32325037
http://dx.doi.org/10.1016/S1473-3099(20)30248-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172913/
https://www.ncbi.nlm.nih.gov/pubmed/32325037
http://dx.doi.org/10.1016/S1473-3099(20)30248-6

Ejemplares similares